Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2018

Open Access 01-12-2018 | Research article

Citral induced apoptosis in MDA-MB-231 spheroid cells

Authors: Siyamak Ebrahimi Nigjeh, Swee Keong Yeap, Norshariza Nordin, Behnam Kamalideghan, Huynh Ky, Rozita Rosli

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Login to get access

Abstract

Background

Breast cancer remains a leading cause of death in women worldwide. Although breast cancer therapies have greatly advanced in recent years, many patients still develop tumour recurrence and metastasis, and eventually succumb to the disease due to chemoresistance. Citral has been reported to show cytotoxic effect on various cancer cell lines. However, the potential of citral to specifically target the drug resistant breast cancer cells has not yet been tested, which was the focus of our current study.

Methods

The cytotoxic activity of citral was first tested on MDA-MB-231 cells in vitro by MTT assay. Subsequently, spheroids of MDA-MB-231 breast cancer cells were developed and treated with citral at different concentrations. Doxorubicin, cisplatin and tamoxifen were used as positive controls to evaluate the drug resistance phenotype of MDA-MB-231 spheroids. In addition, apoptosis study was performed using AnnexinV/7AAD flowcytometry. Aldefluor assay was also carried out to examine whether citral could inhibit the ALDH-positive population, while the potential mechanism of the effect of citral was carried out by using quantitative real time- PCR followed by western blotting analysis.

Results

Citral was able to inhibit the growth of the MDA-MB-231 spheroids when compared to a monolayer culture of MDA-MB-231 cells at a lower IC50 value. To confirm the inhibition of spheroid self-renewal capacity, the primary spheroids were then cultured to additional passages in the absence of citral. A significant reduction in the number of secondary spheroids were formed, suggesting the reduction of self-renewal capacity of these aldehyde dehydrogenase positive (ALDH+) drug resistant spheroids. Moreover, the AnnexinV/7AAD results demonstrated that citral induced both early and late apoptotic changes in a dose-dependent manner compared to the vehicle control. Furthermore, citral treated spheroids showed lower cell renewal capacity compared to the vehicle control spheroids in the mammosphere formation assay. Gene expression studies using quantitative real time PCR and Western blotting assays showed that citral was able to suppress the self-renewal capacity of spheroids and downregulate the Wnt/β-catenin pathway.

Conclusion

The results suggest that citral could be a potential new agent which can eliminate drug-resistant breast cancer cells in a spheroid model via inducing apoptosis.
Literature
1.
go back to reference American Cancer Society. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015. American Cancer Society. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
2.
go back to reference Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee JH, et al. Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anti Cancer Agents Med Chem. 2012;12(10):1281.CrossRef Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee JH, et al. Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anti Cancer Agents Med Chem. 2012;12(10):1281.CrossRef
3.
go back to reference Chaouki W, Leger DY, Liagre B, Beneytout JL, Hmamouchi M. Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells. Fund Clin Pharmacol. 2009;23(5):549–56.CrossRef Chaouki W, Leger DY, Liagre B, Beneytout JL, Hmamouchi M. Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells. Fund Clin Pharmacol. 2009;23(5):549–56.CrossRef
4.
go back to reference Zeng S, Kapur A, Patankar MS, Xiong MP. Formulation, characterization and antitumor properties of trans- and Cis-citral in the 4T1 breast cancer xenograft mouse model. Pharm Res. 2015;32:2548–58.PubMedPubMedCentral Zeng S, Kapur A, Patankar MS, Xiong MP. Formulation, characterization and antitumor properties of trans- and Cis-citral in the 4T1 breast cancer xenograft mouse model. Pharm Res. 2015;32:2548–58.PubMedPubMedCentral
5.
go back to reference Tan EY, Thike AA, Breast Surgical Team at Outram, Tan PH. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Brit J Cancer. 2013;109:109–13.CrossRefPubMedPubMedCentral Tan EY, Thike AA, Breast Surgical Team at Outram, Tan PH. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Brit J Cancer. 2013;109:109–13.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Ho WY, Yeap SK, Ho CL, Rahim RA, Alitheen NB. Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. PLoS One. 2012;7:e44640.CrossRefPubMedPubMedCentral Ho WY, Yeap SK, Ho CL, Rahim RA, Alitheen NB. Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. PLoS One. 2012;7:e44640.CrossRefPubMedPubMedCentral
9.
go back to reference Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. 2011. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survivial. Cancer Res. 2011;71:3991–4001.CrossRefPubMedPubMedCentral Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. 2011. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survivial. Cancer Res. 2011;71:3991–4001.CrossRefPubMedPubMedCentral
10.
go back to reference Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke R. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One. 2013;8:e67811.CrossRefPubMedPubMedCentral Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke R. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One. 2013;8:e67811.CrossRefPubMedPubMedCentral
11.
go back to reference Warrier S, Bhuvanalakshimi G, Arfuso F, Rajan G, Millward M, Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther. 2014;21:381–8.CrossRefPubMed Warrier S, Bhuvanalakshimi G, Arfuso F, Rajan G, Millward M, Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther. 2014;21:381–8.CrossRefPubMed
12.
go back to reference Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS, Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580–90.CrossRefPubMedPubMedCentral Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS, Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580–90.CrossRefPubMedPubMedCentral
13.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer C, Liu S, Schoot A, Hayes D, Bimbum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.CrossRefPubMedPubMedCentral Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer C, Liu S, Schoot A, Hayes D, Bimbum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.CrossRefPubMedPubMedCentral
14.
go back to reference Cravotto G, Binello A, Baranelli E, Carraro P, Trotta F. Cyclodextrins as food additives and in food processing. Curr Nutr Food Sci. 2006;2(4):343–50.CrossRef Cravotto G, Binello A, Baranelli E, Carraro P, Trotta F. Cyclodextrins as food additives and in food processing. Curr Nutr Food Sci. 2006;2(4):343–50.CrossRef
15.
go back to reference Ress NB, Hailey JR, Maronpot RR, Bucher JR, Travlos GS, Haseman JK, et al. Toxicology and carcinogenesis studies of microencapsulated citral in rats and mice. Toxicol Sci. 2003;71(2):198–206.CrossRefPubMed Ress NB, Hailey JR, Maronpot RR, Bucher JR, Travlos GS, Haseman JK, et al. Toxicology and carcinogenesis studies of microencapsulated citral in rats and mice. Toxicol Sci. 2003;71(2):198–206.CrossRefPubMed
16.
go back to reference Ben-Arye E, Attias S, Tadmor T, Schiff E. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leukemia Lymphoma. 2010;51(8):1414–23.CrossRefPubMed Ben-Arye E, Attias S, Tadmor T, Schiff E. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leukemia Lymphoma. 2010;51(8):1414–23.CrossRefPubMed
17.
go back to reference Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64(11):937–46.CrossRefPubMed Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64(11):937–46.CrossRefPubMed
18.
go back to reference Pećina-Šlaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int. 2010;10(1):1.CrossRef Pećina-Šlaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int. 2010;10(1):1.CrossRef
20.
go back to reference Olmeda D, Castel S, Vilaró S, Cano A. β-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell. 2003;14(7):2844–60.CrossRefPubMedPubMedCentral Olmeda D, Castel S, Vilaró S, Cano A. β-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell. 2003;14(7):2844–60.CrossRefPubMedPubMedCentral
21.
go back to reference Hiyama H, Reeves SA. Role for cyclin D1 in UVC-induced and p53-mediated apoptosis. Cell Death Differ. 1999;6(6):565–9. Hiyama H, Reeves SA. Role for cyclin D1 in UVC-induced and p53-mediated apoptosis. Cell Death Differ. 1999;6(6):565–9.
22.
go back to reference Li VSW, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJR, Maurice MM, Mahmoudi T, Clevers H. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012;149:1245–56.CrossRefPubMed Li VSW, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJR, Maurice MM, Mahmoudi T, Clevers H. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012;149:1245–56.CrossRefPubMed
24.
go back to reference White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32.CrossRefPubMed White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32.CrossRefPubMed
25.
go back to reference Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Yong W, Pestell RG, Hung MC. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000;97:4262–6.CrossRefPubMedPubMedCentral Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Yong W, Pestell RG, Hung MC. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000;97:4262–6.CrossRefPubMedPubMedCentral
26.
go back to reference Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253–7.CrossRefPubMedPubMedCentral Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253–7.CrossRefPubMedPubMedCentral
27.
go back to reference Anastas JN, Moon RT. Wnt signaling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed Anastas JN, Moon RT. Wnt signaling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed
28.
go back to reference Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci. 2013;110(50):20224–9.CrossRefPubMedPubMedCentral Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci. 2013;110(50):20224–9.CrossRefPubMedPubMedCentral
Metadata
Title
Citral induced apoptosis in MDA-MB-231 spheroid cells
Authors
Siyamak Ebrahimi Nigjeh
Swee Keong Yeap
Norshariza Nordin
Behnam Kamalideghan
Huynh Ky
Rozita Rosli
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2115-y

Other articles of this Issue 1/2018

BMC Complementary Medicine and Therapies 1/2018 Go to the issue